Organization
Istesso Ltd, London, United Kingdom
2 abstracts
Abstract
A NOVEL SMALL MOLECULE, MBS2133, MODULATES OSTEOCLAST PRE-CURSOR METABOLISM TO INHIBIT OSTEOCLAST DIFFERENTIATION: AN ALTERNATIVE THERAPY FOR OSTEOLYTIC PATHOLOGY IN RAOrg: Istesso Ltd, London, United Kingdom, Johnson and Johnson Innovation, London, United Kingdom, University of Glasgow, University of Liverpool, University of Aberdeen,
Abstract
A FIRST-IN-CLASS METABOLIC REPROGRAMMING AGENT, MBS2320, SELECTIVELY MODULATES IMMUNE CELL FUNCTION AND IMPROVES OSTEOID FORMATION AND BONE PROTECTION VERSUS ETANERCEPT IN THE MOUSE COLLAGEN-INDUCED ARTHRITIS MODELOrg: Istesso Ltd, London, United Kingdom, Johnson and Johnson Pharmaceutical RandD, Spring House, United States of America, Janssen, Beerse, Belgium, Johnson and Johnson Innovation, London, United Kingdom,